Plus Therapeutics, Inc.
PSTVNASDAQHealthcare● Active
$5.70
+$0.17(+2.98%)
Market Cap$13779645
P/E Ratio—
52W High$23.5
52W Low$2.9
Plus Therapeutics, Inc.（PSTV）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · PSTV · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($22.39M) | ($12.98M) | ($13.32M) | ($20.27M) | ($13.40M) |
| Depreciation & Amort. | $0.45M | $0.72M | $0.63M | $0.62M | $0.40M |
| Stock-Based Comp. | $1.54M | $0.55M | $0.57M | $0.61M | $0.61M |
| Change in Working Capital | ($6.04M) | $3.22M | ($1.12M) | $5.60M | $1.24M |
| Net Cash from Operations | ($20.77M) | ($10.55M) | ($12.85M) | ($12.97M) | ($10.28M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.07M) | ($0.15M) | ($0.16M) | ($0.76M) | ($0.14M) |
| Purchases of Investments | ($9.35M) | ($15.59M) | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $8.54M | $12.17M | $0.00M | $0.00M | $0.00M |
| Net Cash from Investing | ($0.85M) | ($4.11M) | ($0.16M) | ($0.76M) | ($0.08M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | ($0.37M) | ($0.13M) | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | ($4.76M) | ($0.70M) | ($1.61M) | ($1.61M) | ($0.28M) |
| Net Cash from Financing | $30.31M | $6.19M | $3.44M | $13.45M | $20.42M |
| Free Cash Flow | |||||
| Free Cash Flow | ($20.84M) | ($10.70M) | ($13.01M) | ($13.73M) | ($10.42M) |
| FCF Margin %(computed) | -399.81% | -183.72% | -264.83% | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · M
深入了解Plus Therapeutics, Inc.
关于Plus Therapeutics, Inc.（PSTV）现金流量表
Plus Therapeutics, Inc. 2025财年经营活动现金流($0.02B)，自由现金流($0.02B)（FCF利润率-399.81%），资本支出($0.00B)。
常见问题
PSTV · 4 问Plus Therapeutics, Inc. 2025财年自由现金流($0.02B)，同比down94.8%。
PSTV free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10